EBLF Health+Benefits

DNA’s Day in Employee Benefits

Leader’s Edge sat down with Wamberg Genomic Advisors’ (WGA) Chief Innovation Officer, Darren Rowe, to talk about the innovation propelling WGA and how genomics promotes a more holistic view of patient health.
By Katie Oberkircher Posted on May 13, 2020

DNA’s Day in Employee Benefits

Hosted by Katie Oberkircher With Guest Darren Rowe, Chief Innovation Officer, Wamberg Genomic Advisors
DNA’s Day in Employee Benefits
0:00
Listen With soundcloud

We caught up with WGA’s Chief Innovation Officer, Darren Rowe, after the onset of the coronavirus to learn more about how WGA reshaped its Cancer Guardian solution to support one of the most vulnerable populations during this pandemic.

Q
Tell me about WGA’s response to COVID-19.
A
We recognized fairly quickly that the implications of COVID-19 could be severe and devastating not just from a health perspective but financially and emotionally. Our colleagues in the medical and science community did a good job keeping us updated and we were fortunate to be able to act quickly. We built our company on a strong digital foundation so we were able to deploy a WFH strategy with minimum disruption. We were also able to repurpose our cancer financial navigation program to help our members access COVID-19 financial assistance. New programs and foundations are being set up every day to help people with the financial challenges this pandemic presents and many are aimed at those with other underlying health conditions (not just cancer).
Q
Routine preventive screenings such as mammograms and colonoscopies have for the most part been tabled as the coronavirus crisis worsens. Now as states look to ease stay-at-home restrictions, physicians are anticipating their clinics will see an influx of new cancer diagnoses and potentially worse prognoses. What does that mean for the cancer community?
A
When we talk to providers, [they say] there’s a been a dramatic drop in the number of people who are going into hospitals for elective treatments, including some cancer-related surgeries. As you say, routine screenings have also been canceled and I suspect many people simply won’t get round to rescheduling and will skip through to next year. I think the delay in seeking medical attention—and screenings—will for some people result in a more advanced and potentially more serious cancer diagnosis. The net effect is likely to be an influx of new diagnoses’ and possibly more advanced stage cancers.

I had a really interesting conversation with somebody who constructs [retirement] packages for individuals and employer clients. They explained that people are diving into their 401(k)s because they are working fewer hours or their spouses have lost their jobs—but they still need [to pay for] medical treatment. They’re taking the money that is there for their future to pay for a problem happening today. If you consider that situation and apply it to a cancer patient, in particular, there’s no question that those individuals, in particular, will be vulnerable both financially and clinically.
Katie Oberkircher Director, Market Intelligence & Insights Read More

More Podcasts

Budding Broker
Brokerage Ops Budding Broker
Q&A with Drew Taylor, Broker, Founder Shield
Industry Young Talent Speaks
A new podcast series
Kabuki Theater, Crazy Lawsuits, Insane Tweets: Our Conversation with Mike Murphy
Health+Benefits Kabuki Theater, Crazy Lawsuits, Insane Tweets: Our Conversation with Mike Murphy
The Council's Joel Wood goes unplugged with Republican political consultant Mike...
On the Mic with David Axelrod
Health+Benefits On the Mic with David Axelrod
The Council's Joel Wood follows up with political analyst David Axelrod for an e...
When Uncertainty Meets Data
Health+Benefits When Uncertainty Meets Data
2020 continues to be an anomaly. Claims and clinical data in...
A Look at the Carrier Perspective on Manufacturing Risk and COVID-19
P&C A Look at the Carrier Perspective on Manufacturing Risk and COVID-19
Back-to-work risk in an industry that never stopped working.